Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.60 | 1.60 | -0.02% |
| CAC 40 | 7,825.96 | 21.29 | 0.27% |
| DAX 40 | 24,350.99 | 74.51 | 0.31% |
| Dow JONES (US) | 42,427.74 | 91.90 | -0.22% |
| FTSE 100 | 8,807.94 | 6.65 | 0.08% |
| HKSE | 23,885.67 | 231.64 | 0.98% |
| NASDAQ | 19,460.49 | 61.53 | 0.32% |
| Nikkei 225 | 37,554.49 | 192.96 | -0.51% |
| NZX 50 Index | 12,577.15 | 82.44 | 0.66% |
| S&P 500 | 5,970.81 | 0.44 | 0.01% |
| S&P/ASX 200 | 8,538.90 | 2.90 | -0.03% |
| SSE Composite Index | 3,384.10 | 7.90 | 0.23% |